Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy of daratumumab in treatment of relapsed and/or refractory warm autoimmune hemolytic anemia in children

View Full Paper
Ask AI
Bookmark
Share

Authors

FMFaryal MunirSSSanjay Shah

Discussion

Loading...

Member takes

Overview

Case series shows daratumumab improves outcomes in pediatric patients with relapsed warm autoimmune hemolytic anemia, implying a new treatment option.

Key Points

  • To assess the efficacy of daratumumab in treating relapsed and refractory warm autoimmune hemolytic anemia in children.
  • Case series approach
  • Retrospective chart review of 4 pediatric patients
  • Patients received daratumumab following other treatments
  • Evaluation of transfusion independence and response times
  • 75% response rate in treated pediatric patients
  • Median time to response was 7 days
  • Median follow-up showed transfusion independence at 12 months
  • Repeat daratumumab courses were effective in some cases

Cite This Study

Munir et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddc5https://doi.org/10.1182/blood-2025-2899
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Posttransplant Autoimmune Hemolytic Anemia with Anti-D Specificity Successfully Treated with Daratumumab: A Case Report2024 · 3 citations
  2. 2Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease2024 · 15 citations
  3. 3P46 Management of autoimmune haemolytic anaemia in a paediatric patient2024 · 1 citations
  4. 4Single low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias2026
  5. 5Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: a case report and literature review2025